Welcome to Africanews

Please select your experience

Watch Live

world

This is a historic moment for the government and people of Ethiopia…

This is a historic moment for the government and people of Ethiopia…

MSD (www.MSD.co.za) congratulates Ethiopia on the successful launch of the National Immunisation Programme (NIP) for the Human-Papillomavirus (HPV - the main cause of cervical cancer).[1]

Each year an estimated 7 095 Ethiopian women are diagnosed with cervical cancer. In 2012 the mortality rate related to cervical cancer for Ethiopian women was 20 per 100 000. Total cancer deaths in females was 26 200 annually, of which 17.5% (4 454) is attributable to cervical cancer.[2]a,b,c

In Sub-Saharan Africa (SSA), cervical cancer incidence rates are the highest in the world and the disease is the most common cause of cancer death among women in the region. HPV16 and 18 are the most common genotypes for cervical cancer in SSA[3]. Although HPV16 and 18 are associated with approximately 70% of cervical cancer cases the various HPV genotypes also contribute to penile cancers, anal cancers, vulvar and vaginal cancers as well as genital warts[4].

The launch of the NIP in Ethiopia is an important step towards achieving the vision of a world where the number of women and men affected by certain HPV-related cancers is greatly reduced. MSD is committed to working with the government of Ethiopia and other partners on the continent to ensure that this goal becomes a reality.

 

[1] https://www.cdc.gov/cancer/cervical/pdf/cervical_facts.pdf

[2] http://www.who.int/cancer/country-profiles/eth_en.pdf?ua=1

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144870/

[4] http://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer

Distributed by APO Group on behalf of MSD.
Media Contact:
Neren Rau
+27 11 655 3000,
neren.rau@merck.com 

About MSD: 
For more than a century, MSD (www.MSD.co.za), a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world’s most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. 
For more information, visit www.MSD.co.za and connect with us on Twitter (https://twitter.com/MSD_SouthAfrica).
MSD
Download logo
Africanews provides content from APO Group as a service to its readers, but does not edit the articles it publishes.